Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor

• Status: Unknown status
• Trial end date: 2019-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The current trial will compare the protective effect of ticagrelor and prasugrel on microvascular dysfunction in patients with revascularized ST elevation myocardial infarction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VU University Medical Center
• Collaborators: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Erasmus Medical Center; Hospital San Carlos, Madrid; Medisch Spectrum Twente; University Medical Center Nijmegen
• Treatments: Prasugrel Hydrochloride; Ticagrelor

Criteria

Inclusion Criteria:

1. Provision of informed consent

2. Patients presenting with ST-elevation myocardial infarction <12 hours after symptom onset

3. Successful percutaneous coronary intervention of the infarct-related vessel with a modern drug-eluting stent

4. Intermediate stenosis in non-infarct-related vessel (50-90%)

Exclusion Criteria:

1. history of myocardial infarction

2. Participation in another clinical study with an investigational product during the preceding 30 days

3. history of cerebrovascular accident (CVA) or 'transient ischaemic attack' (TIA)

4. History of intracranial haemorrhage

5. indication or use of oral anticoagulant therapy (i.e. acenocoumarol)

6. severe liver dysfunction (Child-Pugh score 10-15)

7. congestive heart failure

8. cardiogenic shock

9. left ventricular ejection fraction < 35%

10. bleeding diathesis

11. age ≥ 75 or < 18

12. body weight < 60 kg

13. gout

14. coagulation disorders

15. severe pulmonary disease

16. pregnancy and breast feeding

17. limited life expectancy

18. platelet count < 100 000/mm3

19. history of drug addiction or alcohol abuse in the past 2 years

20. need for chronic nonsteroidal anti-inflammatory drug

21. creatinine clearance <30 mL/min or dialysis

22. chronic total occlusion (CTO)

23. Left main disease

24. allergy or contra-indication for ticagrelor or prasugrel

25. Contra-indication for adenosine

26. Patients unable to be followed on-site

27. Unable to undergo or contra-indications for MRI

28. Contra-indication for drug-eluting stent

29. Inability to obtain informed consent

30. Coronary artery bypass grafting in medical history